Pain Management - Neuropathic Pain

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS – Maximum Days' Supply Allowed	PR – Enrollment in a Physician- Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have 'X' DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana 1-855-242-0802 AmeriHealth Caritas Louisiana 1-800-684-5502 Fee-for-Service (FFS) Louisiana Legacy Medicaid 1-866-730-4357 Healthy Blue 1-844-521-6942 Louisiana Healthcare Connections 1-888-929-3790

UnitedHealthcare 1-800-310-6826

Pain Management - Neuropathic Pain

POS Edits

No additional POS edits apply on all EXCEPT duloxetine and lidocaine patch.

 \mathbf{BH} – Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for duloxetine when requested for recipients who are younger than 7 years of age.

QL – Pharmacy claims for lidocaine patches are limited to 30 patches every rolling 30 days. *Override is available through an authorization process when the recipient has a diagnosis of post-herpetic neuralgia*.

Revision / Date	Implementation Date
Created POS Document	February 2020
Modified to apply new age requirement for behavioral health clinical authorization / November 2020	January 2021